Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00405119 |
Current treatment for gastroesophageal reflux disease (GERD) confirms an unmet need in patients, based on slow onset of action and an inability to provide 24-hour gastric-acid suppression. Clinical data on AH234844 demonstrates a rapid onset of action, high potency, and prolonged duration of effect. The present study endeavors, in part, to compare lavoltidine to two GERD drugs, NEXIUM and ranitidine.
Condition | Intervention | Phase |
---|---|---|
Gastroesophageal Reflux Disease |
Drug: AH23844 (lavoltidine) Drug: NEXIUM (esomeprazole) Drug: ZANTAC (ranitidine) |
Phase II |
Study Type: | Interventional |
Study Design: | Diagnostic, Randomized, Double-Blind, Crossover Assignment, Pharmacokinetics/Dynamics Study |
Official Title: | See Detailed Description |
Enrollment: | 92 |
Study Start Date: | May 2006 |
A three-part study in healthy male volunteers to determine the most effective of four different lavoltidine doses on gastric pH and to compare the most effective dose with NEXIUM (esomeprazole) 40mg for the inhibition of gastric-acid secretion and with ranitidine (300mg/day) for the amount of pharmacodynamic tolerance
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Inclusion criteria:
Exclusion criteria:
Australia, New South Wales | |
GSK Investigational Site | |
Randwick, New South Wales, Australia, 2031 | |
Australia, Queensland | |
GSK Investigational Site | |
Herston, Queensland, Australia, 4006 |
Study Director: | GSK Clinical Trials | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | LAV104616 |
Study First Received: | November 27, 2006 |
Last Updated: | October 15, 2008 |
ClinicalTrials.gov Identifier: | NCT00405119 |
Health Authority: | Australia: Department of Health and Ageing Therapeutic Goods Administration |
AH23844 gastroesophageal reflux disease (GERD) pharmacokinetics pharmacodynamics |
tolerance ranitidine esomeprazole |
Bismuth tripotassium dicitrate Esophageal disorder Gastrointestinal Diseases Citric Acid Omeprazole Gastroesophageal Reflux Histamine Bismuth |
Esophageal Motility Disorders Deglutition Disorders Ranitidine Digestive System Diseases Ranitidine bismuth citrate Histamine phosphate Esophageal Diseases Loxtidine |
Neurotransmitter Agents Histamine Antagonists Molecular Mechanisms of Pharmacological Action Therapeutic Uses Physiological Effects of Drugs Anti-Ulcer Agents |
Gastrointestinal Agents Histamine Agents Enzyme Inhibitors Histamine H2 Antagonists Pharmacologic Actions |